Total cholesterol (CHOL)
levels have been shown in many studies, to be higher in people with several
types of cancer. Similar results are observed for both triglycerides (TG) and
low-density cholesterol (LDL), as opposed to high-density cholesterol (HDL). Chemotherapy
seems to reduce CHOL and LDL, leading to a reduction. Furthermore, the
recurrence of high levels of CHOL, TG and LDL, as well as low levels of HDL,
after receiving treatment, or when patients appear to have been cured, are
signs of a possible recurrence of the disease. Lipoprotein α (Lpa),
occurs at higher levels in patients than in healthy people, whereas lipokines
resistin and bisfatin, “hormonal” products of adipose tissue exhibited high
levels in cancer cases, compared to control groups.
References
[1]
Large, V., Peroni, O., Letexier, D., Ray, H. and Beylot, M. (2004) Metabolism of Lipids in Human White Adipocyte. Diabetes & Metabolism, 30, 294-309. https://doi.org/10.1016/S1262-3636(07)70121-0
[2]
Wolin, K.Y., Carson, K. and Colditz, G.A. (2010) Obesity and Cancer. Oncologist, 15, 556-565. https://doi.org/10.1634/theoncologist.2009-0285
[3]
Vance, J.E. and Vance, D. (2008) Biochemistry of Lipids, Lipoproteins and Membranes. 5th Edition, Elsevier, Amsterdam, 8-9.
[4]
Mattes, R.D. (2005) Fat Taste and Lipid Metabolism in Humans. Physiology & Behavior, 86, 691-697. https://doi.org/10.1016/j.physbeh.2005.08.058
[5]
Zechner, R., Zimmermann, R., Eichmann, T.O., Kohlwein, S.D., Haemmerle, G., Lass, A. and Madeo, F. (2012) Fat Signals—Lipases and Lipolysis in Lipid Metabolism and Signaling. Cell Metabolism, 15, 279-291. https://doi.org/10.1016/j.cmet.2011.12.018
[6]
Fahy, E., Cotter, D., Sud, M. and Subramaniam, S. (2011) Lipid Classification, Structures and Tools. Biochim et Biophys Acta: Molecular and Cell Biology of Lipids, 1811, 637-647. https://doi.org/10.1016/j.bbalip.2011.06.009
[7]
Santos, C.R. and Schulze, A. (2012) Lipid Metabolism in Cancer. The FEBS Journal, 279, 2610-2623. https://doi.org/10.1111/j.1742-4658.2012.08644.x
[8]
Hsu, P.P. and Sabatini, D.M. (2008) Cancer Cell Metabolism: Warburg and Beyond. Cell, 134, 703-707. https://doi.org/10.1016/j.cell.2008.08.021
[9]
Menendez, J.A. and Lupu, R. (2007) Fatty Acid Synthase and the Lipogenic Phenotype in Cancer Pathogenesis. Nature Reviews Cancer, 7, 763-777. https://doi.org/10.1038/nrc2222
[10]
Zaidi, N., Lupien, L., Kuemmerle, N.B., Kinlaw, W.B., Swinnen, J.V. and Smans, K. (2013) Lipogenesis and Lipolysis: The Pathways Exploited by the Cancer Cells to Acquire Fatty Acids. Progress in Lipid Research, 52, 585-589. https://doi.org/10.1016/j.plipres.2013.08.005
Grundy, S.M. (2004) Obesity, Metabolic Syndrome, and Cardiovascular Disease. The Journal of Clinical Endocrinology & Metabolism, 89, 2595-2600. https://doi.org/10.1210/jc.2004-0372
[13]
Munir, R., Usman, H., Hasnain, S., Smans, K., Kalbacher, H. and Zaidi, N. (2014) Atypical Plasma Lipid Profile in Cancer Patients: Cause or Consequence. Biochinie, 102, 9-18. https://doi.org/10.1016/j.biochi.2014.03.010
[14]
Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancerrelated Inflammation. Nature, 454, 436-444. https://doi.org/10.1038/nature07205
[15]
Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. https://doi.org/10.1038/nature01322
[16]
Alexandrov, L.B., Nik-Zainal, S., Wedge, D., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. (2013) Signatures of Mutational Processes in Human Cancer. Nature, 500, 415-421. https://doi.org/10.1038/nature12477
[17]
Iyengar, N.M., Hudis, C.A. and Dannenberg, A.J. (2015) Obesity and Cancer: Local and Systemic Mechanisms. Annual Review of Medicine, 66, 297-309. https://doi.org/10.1146/annurev-med-050913-022228
[18]
Lengauer, C., Kinzler, K.W. and Vogelstein, B. (1998) Genetic Instabilities in Human Cancers. Nature, 396, 643-649. https://doi.org/10.1038/25292
[19]
Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., et al. (2011) Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 144, 27-40.
[20]
Sansregret, L., Vanhaesebroeck, B. and Swanton, C. (2018) Determinants and Clinical Implications of Chromosomal Instability in Cancer. Nature Reviews Clinical Oncology, 15, 139-150. https://doi.org/10.1038/nrclinonc.2017.198
[21]
Jain, R.K. (2005) Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science, 307, 58-62. https://doi.org/10.1126/science.1104819
[22]
Minchinton, A.I. and Tannock, I.F. (2006) Drug Penetration in Solid Tumours. Nature Reviews Cancer, 6, 583-592. https://doi.org/10.1038/nrc1893
[23]
Goldie, J.H. and Coldman, A.J. (1984) The Genetic Origin of Drug Resistance in Neoplasms: Implications for Systemic Therapy. Cancer Research, 44, 3643-3653.
[24]
Fisher, B., Slack, N.H. and Bross, I.D. (1969) Cancer of the Breast: Size of Neoplasm and Prognosis. Cancer, 24, 1071-1080. https://doi.org/10.1002/1097-0142(196911)24:5<1071::AID-CNCR2820240533>3.0.CO;2-H
[25]
Skipper, H.E., Schabel Jr., F.M. and Wilcox, W.S. (1964) Experimental Evaluation of Potential Anticancer Agents. XIII. On the Criteria and Kinetics Associated with “Curability” of Experimental Leukemia. Cancer Chemotherapy Reports, 35, 1-111.
[26]
Sharma, P., Hu-Lieskovan, S., Wargo, J.A. and Ribas, A. (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168, 707-723. https://doi.org/10.1016/j.cell.2017.01.017
[27]
Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., et al. (2008) Modelling Myc Inhibition as a Cancer Therapy. Nature, 455, 679-683. https://doi.org/10.1038/nature07260
[28]
Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A. and Shokat, K.M. (2013) K-Ras(G12C) Inhibitors Allosterically Control GTP Affinity and Effector Interactions. Nature, 503, 548-551. https://doi.org/10.1038/nature12796
[29]
Lambert, J.M., Gorzov, P., Veprintsev, D.B.,Söderqvist, M., Segerbäck, D., Bergman, J., et al. (2009) PRIMA-1 Reactivates Mutant P53 by Covalent Binding to the Core Domain. Cancer Cell, 15, 376-388. https://doi.org/10.1016/j.ccr.2009.03.003
[30]
Timovska, Y., Pivnyuk, V., Todor, I., Anikusko, N. and Chekhun, V. (2011) The Spectrum of Blood Serum Lipids in Patients with Breast Cancer without Metabolic Syndrome. Experimental Oncology, 33, 190-192.
[31]
Agurs-Collins, T., Kim, K.S., Dunston, G.M. and Adams-Campbell, L.L. (1998) Plasma Lipid Alterations in African-American Women with Breast Cancer. Journal of Cancer Research and Clinical Oncology, 124, 186-190. https://doi.org/10.1007/s004320050153
[32]
Delimaris, I., Faviou, E., Antonakos, G., Stathopoulou, E., Zachari, A. and Dionyssiou-Asteriou, A. (2007) Oxidized LDL, Serum Oxidizability and Serum Lipid Levels in Patients with Breast or Ovarian Cancer. Clinical Biochemistry, 40, 1129-1134. https://doi.org/10.1016/j.clinbiochem.2007.06.007
[33]
Abdelsalam, K.E., Hassan, I.K. and Sadig, I.A. (2012) The Role of Developing Breast Cancer in Alteration of Serum Lipid Profile. Journal of Research in Medical Sciences 17, 562-565.
[34]
Bhat, S.A., Mir, M.R., Majid, S., Reshi, A.A., Husain, I., Hassan, T. and Ahmad, H. (2013) Serum Lipid Profile of Breast Cancer Patients in Kashmir. American Journal of Physiology, Biochemistry and Pharmacology, 2, 26-31. https://doi.org/10.5455/jib.20121125075314
[35]
Hasija, K. and Bagga, H.K. (2005) Alterations of Serum Cholesterol and Serum Lipoprotein in Breast Cancer of Women. Indian Journal of Clinical Biochemistry, 20, 61-66. https://doi.org/10.1007/BF02893044
[36]
Liu, Y.L., Qian, H.X., Qin, L., Zhou, X.J., Zhang, B. and Chen, X. (2012) Association of Serum Lipid Profile with Distant Metastasis in Breast Cancer Patients. Chinese Journal of Oncology, 34, 129-131
[37]
Bahl, M., Ennis, M., Tannock, I.F., Hux, J.E., Pritchard, K.I., Koo, J. and Goodwin, P.J. (2005) Serum Lipids and Outcome of Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Breast Cancer Research and Treatmen, 94, 135-144. https://doi.org/10.1007/s10549-005-6654-9
[38]
Eliassen, A.H., Colditz, G.A., Rosner, B., Willett, W.C. and Hankinson, S.E. (2005) Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer. Archives of Internal Medicine, 165, 2264-2271. https://doi.org/10.1001/archinte.165.19.2264
[39]
Thangaraju, M., Kumar, K., Gandhirajan, R. and Sachdanandam, P. (1994) Effect of Tamoxifen on Plasma Lipids and Lipoproteins in Postmenopausal Women with Breast Cancer. Cancer, 73, 659-663. https://doi.org/10.1002/1097-0142(19940201)73:3<659::AID-CNCR2820730325>3.0.CO;2-H
[40]
Knapp, M., Al-Sheibani, S. and Riches, P. (1991) Alterations of Serum Lipids in Breast Cancer: Effects of Disease Activity, Treatment, and Hormonal Factors. Clinical Chemistry, 37, 2093-2101. https://doi.org/10.1093/clinchem/37.12.2093
[41]
Hoyer, A.P. and Engholm, G. (1992) Serum Lipids and Breast Cancer Risk: A Cohort Study of 5,207 Danish Women. Cancer Causes & Control, 3, 403-408. https://doi.org/10.1007/BF00051352
[42]
Laisupasin, P., Thompat, W., Sukarayodhin, S., Sornprom, A. and Sudjaroen, Y. (2013) Comparison of Serum Lipid Profiles between Normal Controls and Breast Cancer Patients. Journal of Laboratory Physicians, 5, 38-41. https://doi.org/10.4103/0974-2727.115934
[43]
Furberg, A.S., Jasienska, G., Bjurstam, N., Torjesen, P.A., Emaus, A., Lipson, S.F., Ellison, P.T. and Thune, I. (2005) Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention, 14, 33-40.
[44]
Furberg, A.S., Veierod, M.B., Wilsgaard, T., Bernstein, L. and Thune, I. (2004) Serum Highdensity Lipoprotein Cholesterol, Metabolic Profile, and Breast Cancer Risk. JNCI: Journal of the National Cancer Institute, 96, 1152-1160. https://doi.org/10.1093/jnci/djh216
[45]
Lindemann, K., Vatten, L.J., Ellstrom-Engh, M. and Eskild, A. (2009) Serum Lipids and Endometrial Cancer Risk: Results from the HUNT-II Study. International Journal of Cancer, 124, 2938-2941. https://doi.org/10.1002/ijc.24285
[46]
Seth, D., Garmo, H., Wigertz, A., Holmberg, L., Hammar, N., Jungner, I., Lambe, M., Walldius, G. and Van Hemelrijck, M. (2012) Lipid Profiles and the Risk of Endometrial Cancer in the Swedish AMORIS Study. International Journal of Molecular Epidemiology and Genetics, 3, 122-133.
[47]
Allott, E., Howard, L., Cooperberg, M.R., Kane, C., Aronson, W.J., Terris, M., Amling, C. and Freedland, S. (2014) Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology, Biomarkers & Prevention, 23, 2349-2356. https://doi.org/10.1158/1055-9965.EPI-14-0458
[48]
Salgado-Montilla, J., Salgado, M., Trautmann, B., Sánchez-Ortiz, R. and Irizarry-Ramírez, M. (2015) Association of Serum Lipid Levels and Prostate Cancer Severity among Hispanic Puerto Rican Men. Lipids in Health and Disease, 14, Article No. 111. https://doi.org/10.1186/s12944-015-0096-0
[49]
Zhang, G., Qin, X.J., Zhang, H.L., Xiao, W.J., Zhu, Y., Gu, C.Y., Dai, B., Shi, G.H. and Ye, D.W. (2015) Serum Lipid Profiles: Novel Biomarkers Predicting Advanced Prostate Cancer in Patients Receiving Radical Prostatectomy. Asian Journal of Andrology, 17, 239-244. https://doi.org/10.4103/1008-682X.142135
[50]
Qiming, S.C., Ding, Z.G. and Li, G. (2019) Influence of Serum Total Cholesterol, LDL, HDL, and Triglyceride on Prostate Cancer Recurrence after Radical Prostatectomy. Cancer Management and Research, 11, 6651-6661. https://doi.org/10.2147/CMAR.S204947
[51]
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum HDL Cholesterol Concentration in Patients with Squamous Cell and Small Cell Lung Cancer. International Journal of Molecular Medicine, 6, 307-318. https://doi.org/10.3892/ijmm.6.3.307
[52]
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum Total Cholesterol and Triglycerides Levels in Patients with Lung Cancer. International Journal of Molecular Medicine, 5, 201-205. https://doi.org/10.3892/ijmm.5.2.201
[53]
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum LDL Cholesterol Concentration and Lipoprotein Electrophoresis Pattern in Patients with Small Cell Lung Cancer. International Journal of Molecular Medicine, 5, 55-62. https://doi.org/10.3892/ijmm.5.1.55
[54]
Zhan, C.-Z., Zhao, X.-W., Liu, D.-B., Han, C.-Z., Du, L.-L. and Jing, J.-X. (2014) Lipid Levels in Serum and Cancerous Tissues of Colorectal Cancer Patients. World Journal of Gastroenterology, 20, 8646-8652. https://doi.org/10.3748/wjg.v20.i26.8646
[55]
Iso, H., Ikeda, A., Inoue, M., Sato, S. and Tsugane, S. (2009) Serum Cholesterol Levels in Relation to the Incidence of Cancer: The JPHC Study Cohorts. International Journal of Cancer, 125, 2679-2686. https://doi.org/10.1002/ijc.24668
[56]
Brantleya, K., Riisc, A., Erichsenc, R., Thorlacius-Ussinge, O., Jon Møllerf, H. and Lasha, T. (2020) the Association of Serum Lipid Levels with Colorectal Cancer Recurrence. Cancer Epidemiology, 66, Article ID: 101725. https://doi.org/10.1016/j.canep.2020.101725
[57]
Chandler, P.D., Song, Y., Lin, L., Zhang, S., Sesso, H.D. and Mora, S. (2016) Lipid Biomarkers and Long-Term Risk of Cancer in the Women’s Health Study. The American Journal of Clinical Nutrition, 6, 1397-1407. https://doi.org/10.3945/ajcn.115.124321
[58]
Yang, M.H., Rampal, S., Sung, J., Choi, Y.-H., Son, H.J., Lee, J.H., Kim, Y.H., Chang, D.K., Rhee, P-L. and Kim, J.J. (2013) the Association of Serum Lipids with Colorectal Adenomas. American Journal of Gastroenterology, 108, 833-841. https://doi.org/10.1038/ajg.2013.64
[59]
Lippi, G., Franchini, M., Salvagno, G.L. and Guidi, G.C. (2007) Lipoprotein[a] and Cancer: Anti-Neoplastic Effect besides Its Cardiovascular Potency. Cancer Treatment Reviews, 33, 427-436. https://doi.org/10.1016/j.ctrv.2007.02.006
[60]
Leibundgut, G., Scipione, C., Yin, H., Schneider, M., Boffa, M.B., Green, S., Yang, X., Dennis, E., Witztum, J.L., Koschinsky, M.L. and Tsimikas, S. (2013) Determinants of Binding of Oxidized Phospholipids on Apolipoprotein (a) and Lipoprotein (a). Journal of Lipid Research, 54, 2815-2830. https://doi.org/10.1194/jlr.M040733
[61]
Orso, E. and Schmitz, G. (2017) Lipoprotein(a) and Its Role in Inflammation, Atherosclerosis and Malignancies. Clinical Research in Cardiology Supplements, 12, 31-37. https://doi.org/10.1007/s11789-017-0084-1
[62]
Constans, J., Wendling, G., Peuchant, E., Camilleri, G. and Conri, C. (1996) Lipoprotein(a) in 505 Hospitalized Patients with Various Pathological States: Correlations with Cardiovascular Diseases and Therapies. International Angiology, 15, 1-5.
[63]
Wang, M. and Zhang, Y. (2019) High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate. Dis Markers, 2019, Article ID: 9483935. https://doi.org/10.1155/2019/9483935
[64]
Marrera, M., Wagnera, A., Le Montayed, M., Luce, G., Amouyel, P., Dallongeville, J., Ducimetiere, P., Bingham, A., Arveiler, D. and Veltena, M. (2013) Lipoprotein(a) Plasma Levels and the Risk of Cancer: The PRIME Study. European Journal of Cancer Prevention, 22, 286-293. https://doi.org/10.1097/CEJ.0b013e328359cba7
[65]
Motta, M., Giugno, I., Ruello, P., Pistone, G., Di Fazio, I. and Malaguarnera, M. (2001) Lipoprotein(a) Behaviour in Patients with Hepatocellular Carcinoma. Minerva Medica, 92, 301-305.
[66]
Jiang, J., Nilsson-Ehle, P. and Xu, N. (2006) Influence of Liver Cancer on Lipid and Lipoprotein Metabolism. Lipids in Health and Disease, 5, Article No. 4. https://doi.org/10.1186/1476-511X-5-4
[67]
Xu, J., Qiu, X., Li, Y., Sun, N., Zhang, Y. and Shu, J. (2020) Hyperlipoproteinemia (a) Is Associated with Breast Cancer in a Han Chinese Population. Medicine, 99, Article No. e22037. https://doi.org/10.1097/MD.0000000000022037
[68]
Sawabe, M., Tanaka, N. and Mieno, M.N. (2012) Low Lipoprotein(a) Concentration Is Associated with Cancer and All-Cause Deaths: A Population-Based Cohort Study. PLoS ONE, 7, Article ID: e31954. https://doi.org/10.1371/journal.pone.0031954
[69]
Kokoglu, E., Karaarslan, I. and Karaarslan, H.M. (1994) Elevated Serum Lp(a) Levels in the Early and Advanced Stages of Breast Cancer. Cancer Biochemistry Biophysics, 14, 133-136.
[70]
Kuesel, A.C., Kroft, T., Prefontaine, M. and Smith, I.C. (1992) Lipoprotein(a) and CA125 Levels in the Plasma of Patients with Benign and Malignant Ovarian Disease. International Journal of Cancer, 52, 341-346. https://doi.org/10.1002/ijc.2910520302
[71]
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S. and Lazar, M.A. (2001) the Hormone Resistin Links Obesity to Diabetes. Nature, 409, 307-312. https://doi.org/10.1038/35053000
[72]
Savage, D.B., Sewter, C.P., Klenk, E.S., Segal, D.G., Vidal-Puig, A., Considine, R.V. and O’Rahilly, S. (2001) Resistin/Fizz3 Expression in Relation to Obesity and Peroxisome Proliferator-Activated Receptor-γ Action in Humans. Diabetes, 50, 2199-2202. https://doi.org/10.2337/diabetes.50.10.2199
[73]
Lehrke, M., Reilly, M.P., Millington, S.C., Iqbal, N., Rader, D.J. and Lazar, M.A. (2004) An Inflammatory Cascade Leading to Hyperresistinemia in Humans. PLoS Medicine, 1, Article No. e45. https://doi.org/10.1371/journal.pmed.0010045
[74]
Danese, E., Montagnana, M., Minicozzi, A.M., Bonafini, S., Ruzzenente, O., Gelati, M., De Manzoni, G., Lippi, G. and Guidi, G.C. (2012) The Role of Resistin in Colorectal Cancer. Clinica Chimica Acta, 413, 760-764. https://doi.org/10.1016/j.cca.2012.01.019
[75]
Assiri, A.M., Kamel, H.F. and Hassanien, M.F. (2015) Resistin, Visfatin, Adiponectin, and Leptin: Risk of Breast Cancer in Pre- and Postmenopausal Saudi Females and Their Possible Diagnostic and Predictive Implications as Novel Biomarkers. Disease Markers, 2015, Article ID: 253519, 9 Pages. https://doi.org/10.1155/2015/253519
[76]
Assiri, A.M. and Kamel, H.F. (2016) Evaluation of Diagnostic and Predictive Value of Serum Adipokines: Leptin, Resistin and Visfatin in Postmenopausal Breast Cancer. Obesity Research & Clinical Practice, 10, 442-453. https://doi.org/10.1016/j.orcp.2015.08.017
[77]
Kang, J.H., Yu, B.Y. and Youn, D.S. (2007) Relationship of Serum Adiponectin and Resistin Levels with Breast Cancer Risk. Journal of Korean Medical Science, 22, 117-121. https://doi.org/10.3346/jkms.2007.22.1.117
[78]
Dalamaga, M., Karmaniolas, K., Papadavid, E., Pelekanos, N., Sotiropoulos, G. and Lekka, A. (2013) Hyperresistinemia Is Associated with Postmenopausal Breast Cancer. Menopause, 20, 845-851. https://doi.org/10.1097/GME.0b013e31827f06dc
[79]
Gunter, M.J., Wang, T., Cushman, M., Xue, X., Wassertheil-Smoller, S., Strickler, H.D., Rohan, T.E., Manson, J.E., McTiernan, A., Kaplan, R.C., Scherer, P.E., Chlebowski, R.T., Snetselaar, L., Wang, D. and Ho, G.Y. (2015) Circulating Adipokines and Inflammatory Markers and Postmenopausal Cancer Risk. JNCI: Journal of the National Cancer Institute, 107, djv169. https://doi.org/10.1093/jnci/djv169
[80]
Mu~noz-Palomeque, A., Guerrero-Ramirez, M.A., Rubio-Chavez, L.A., Rosales-Gomez, R.C., Lopez-Cardona, M.G., Barajas-Avila, V.H., Delgadillo-Barrera, A., Canton-Romero, J.C., Montoya-Fuentes, H., Garcia-Cobian, T.A. and Gutierrez-Rubio, S.A. (2018) Association of RETN and CAP1 SNPs, Expression and Serum Resistin Levels with Breast Cancer in Mexican Women. Genetic Testing and Molecular Biomarkers, 22, 209-217. https://doi.org/10.1089/gtmb.2017.0212
[81]
Crisostomo, P., Matafome, D., Santos-Silva, A.L., Gomes, M., Gomes, M., Patricio, L., Letra, A.B., Sarmento-Ribeiro, L. and Seica, S.R. (2016) Hyperresistinemia and Metabolic Dysregulation: A Risky Crosstalk in Obese Breast Cancer. Endocrine, 53, 433-442. https://doi.org/10.1007/s12020-016-0893-x
[82]
Salageanu, A., Tucureanu, C. and Lerescu, L. (2010) Serum Levels of Adipokines Resistin and Leptin in Patients with Colon Cancer. Journal of Medicine and Life, 3, 416-420.
[83]
Nakajima, T.E., Yamada, Y. and Hamano, T. (2010) Adipocytokines as New Promising Markers of Colorectal Tumors: Adiponectin for Colorectal Adenoma, and Resistin and Visfatin for Colorectal Cancer. Cancer Science, 101, 1286-1291. https://doi.org/10.1111/j.1349-7006.2010.01518.x
[84]
Gonullu, G., Kahraman, H., Bedir, A., Bektas, A. and Yucel, I. (2010) Association between Adiponectin, Resistin, Insulin Resistance, and Colorectal Tumors. International Journal of Colorectal Disease, 25, 205-212. https://doi.org/10.1007/s00384-009-0828-6
[85]
Diakowska, D., Markocka-Mdczka, K., Szelachowski, P. and Grabowski, K. (2014) Serum Levels of Resistin, Adiponectin, and Apelin in Gastroesophageal Cancer Patients. Disease Markers, 2014, Article ID: 619649. https://doi.org/10.1155/2014/619649
[86]
Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S. and McNiece, I. (1994) Cloning and Characterization of the CDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor. Molecular and Cellular Biology, 14, 1431-1437. https://doi.org/10.1128/mcb.14.2.1431-1437.1994
[87]
Preiss, J. and Handler, P. (1957) Enzymatic Synthesis of Nicotinamide Mononucleotide. Journal of Biological Chemistry, 225, 759-770. https://doi.org/10.1016/S0021-9258(18)64875-6
[88]
Rongvaux, A., Shea, R.J., Mulks, M.H., Gigot, D., Urbain, J., Leo, O. and Andris, F. (2002) Pre-B-Cell Colony-Enhancing Factor, Whose Expression Is Up-Regulated in Activated Lymphocytes, Is a Nicotinamide Phosphoribosyltransferase, a Cytosolic Enzyme Involved in NAD Biosynthesis. European Journal of Immunology, 32, 3225-3234. https://doi.org/10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L
[89]
Luk, T., Malam, Z. and Marshall, J.C. (2008) Pre-B Cell Colony-Enhancing Factor (PBEF)/Visfatin: A Novel Mediator of Innate Immunity. Journal of Leukocyte Biology, 83, 804-816. https://doi.org/10.1189/jlb.0807581
[90]
Murphy, K.G. and Bloom, S.R. (2006) Are All Fats Created Equal. Nature Medicine, 12, 32-33. https://doi.org/10.1038/nm0106-32
[91]
Revollo, J.R., Grimm, A.A. and Imai, S. (2004) the NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells. Journal of Biological Chemistry, 279, 50754-50763. https://doi.org/10.1074/jbc.M408388200
[92]
Curat, C.A., Wegner, V., Sengenes, C., Miranville, A., Tonus, C., Busse, R. and Bouloumie, A. (2006) Macrophages in Human Visceral Adipose Tissue: Increased Accumulation in Obesity and a Source of Resistin and Visfatin. Diabetologia, 49, Article No. 744. https://doi.org/10.1007/s00125-006-0173-z
[93]
Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigne, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpene, C., Audigier, Y., Saulnier-Blache, J.S. and Valet, P. (2005) Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 146, 1764-1771. https://doi.org/10.1210/en.2004-1427
[94]
Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M.R., Stumvoll, M. and Bluher, M. (2005) Plasma Visfatin Concentrations and Fat Depot-Specific MRNA Expression in Humans. Diabetes, 54, 2911-2916. https://doi.org/10.2337/diabetes.54.10.2911
[95]
Dalamaga, M., Karmaniolas, K., Papadavid, E., Pelekanos, N., Sotiropoulos, G. and Lekka, A. (2011) Elevated Serum Visfatin/nicotinamide Phosphoribosyl-Transferase Levels Are Associated with Risk of Postmenopausal Breast Cancer Independently from Adiponectin, Leptin, and Anthropometric and Metabolic Parameters. Menopause, 18, 1198-1204. https://doi.org/10.1097/gme.0b013e31821e21f5
[96]
Dalamaga, M., Archondakis, S., Sotiropoulos, G., Karmaniolas, K., Pelekanos, N., Papadavid, E. and Lekka, A. (2012) Could Serum Visfatin Be a Potential Biomarker for Postmenopausal Breast Cancer. Maturitas, 71, 301-308. https://doi.org/10.1016/j.maturitas.2011.12.013
[97]
Li, X.Y., Tang, S.H., Zhou, X.C., Ye, Y.H., Xu, X.Q. and Li, R.Z. (2014) Preoperative Serum Visfatin Levels and Prognosis of Breast Cancer among Chinese Women. Peptides, 51, 86-90. https://doi.org/10.1016/j.peptides.2013.11.010
[98]
Hung, A.C., Lo, S., Hou, M.F., Lee, Y.C., Tsai, C.H., Chen, Y.Y., Liu, W., Su, Y.H., Lo, Y.H., Wang, C.H., Wu, S.C., Hsieh, Y.C., Hu, S.C., Tai, M.H., Wang, Y.M. and Yuan, S.S. (2016) Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through C-Abl and STAT3 Activation. Clinical Cancer Research, 22, 4478-4490. https://doi.org/10.1158/1078-0432.CCR-15-2704
[99]
Zhu, Y., Guo, M., Zhang, L., Xu, T., Wang, L. and Xu, G. (2016) Biomarker Triplet NAMPT/ VEGF/HER2 as a De Novo Detection Panel for the Diagnosis and Prognosis of Human Breast Cancer. Oncology Reports, 35, 454-462. https://doi.org/10.3892/or.2015.4391
[100]
Rodrigo, C., Tennekoon, K.H., Karunanayake, E.H., De Silva, K., Amarasinghe, I. and Wijayasiri, A. (2017) Circulating Leptin, Soluble Leptin Receptor, Free Leptin Index, Visfatin and Selected Leptin and Leptin Receptor Gene Polymorphisms in Sporadic Breast Cancer. Endocrine Journal, 64, 393-401. https://doi.org/10.1507/endocrj.EJ16-0448
[101]
Cymbaluk-PBoska, A., Chudecka-GBaz, A., Pius-Sadowska, E., Sompolska-RzechuBa, A., MachaliNski, B. and Menkiszak, J. (2018) Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. BioMed Research International, January, 2018, Article ID: 8576179. https://doi.org/10.1155/2018/8576179
[102]
Ilhan, T., Kebapcilar, A. and Yilmaz, S. (2015) Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with Its Prognosis. Asian Pacific Journal of Cancer Prevention, 16, 4503-4508. https://doi.org/10.7314/APJCP.2015.16.11.4503
[103]
Avcioglu, S., Altinkaya, S., Küçük, M., Yüksel, H., Ömürlü, I. and Yanik, S. (2015) Visfatin Concentrations in Patients with Endometrial Cancer. Gynecological Endocrinology, 31, 202-207. https://doi.org/10.3109/09513590.2014.975687
[104]
Tian, W., Zhu, Y. and Wang, Y. (2013) Visfatin, a Potential Biomarker and Prognostic Factor for Endometrial Cancer. Gynecologic Oncology, 129, 505-512. https://doi.org/10.1016/j.ygyno.2013.02.022
[105]
Tian, W.Y., Wang, Y.M., Zhang, Y.F. and Xue, F.X. (2017) The Research Advances in the Relationship between Visfatin and Cancer. Chinese Journal of Oncology, 39, 321-324.
[106]
Fazeli, M.S., Dashti, H., Akbarzadeh, S., Assadi, M., Aminian, A., Keramati, M.R. and Nabipour, I. (2013) Circulating Levels of Novel Adipocytokines in Patients with Colorectal Cancer. Cytokine, 62, 81-85. https://doi.org/10.1016/j.cyto.2013.02.012
[107]
Sun, Y., Zhu, S., Wu, Z., Huang, Y., Liu, C., Tang, S. and Wei, L. (2017) Elevated Serum Visfatin Levels Are Associated with Poor Prognosis of Hepatocellular Carcinoma. Oncotarget, 8, 23427-23435. https://doi.org/10.18632/oncotarget.15080
[108]
Ninomiya, S., Shimizu, M., Imai, K., Takai, K., Shiraki, M., Hara, T., Tsurumi, H., Ishizaki, S. and Moriwaki, H. (2011) Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells. Cancer Prevention Research, 4, 2092-2100. https://doi.org/10.1158/1940-6207.CAPR-11-0340
[109]
Luhn, P., Dallal, C. and Weiss, J. (2013) Circulating Adipokine Levels and Endometrial Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology, 22, 1304-1312. https://doi.org/10.1158/1055-9965.EPI-13-0258
[110]
Lu, G.W., Wang, Q.J., Xia, M.M. and Qian, J. (2014) Elevated Plasma Visfatin Levels Correlate with Poor Prognosis of Gastric Cancer Patients. Peptides, 58, 60-64. https://doi.org/10.1016/j.peptides.2014.05.016
[111]
Sourra, E.N., Sevastou, A., Villiotou, V. and Karikas, G.A. (2015) Correlation of Serum Lipid Concentrations in Patients with Acute Lymphoblastic Leukemia. Epitheorisi Klinikes Farmacologias Kai Farmakokinetikis, 33, 25.
